Figure 2.
The forest plot of studies evaluating the prognostic value of CD133 overexpression in determining the PFS of patients with high-grade gliomas; Rikke H Dahlrot (IV) pertains to the Dahlrot et al.’s study on patients with grade IV gliomas, and Rikke H Dahlrot pertains to the Dahlrot et al.’s study on patients with grade III gliomas.